Oncomine Comprehensive Assay v2

Oncomine is an amplicon-based targeted Next-Generation Sequencing (NGS) test for the identification of clinically significant somatic mutations from the DNA and RNA of 143 cancer-related genes.  Alterations identified include single nucleotide variants (SNVs), insertions and deletions (indels), copy number alterations (CNAs), and oncogenic fusions (greater than 2,500 amplicons) in solid tumors.


Acceptable Specimens: 


Formalin-fixed paraffin embedded tissue:  One Hematoxylin and Eosin (H&E) slide and 15-20 unstained sections with a minimum of 20-percent neoplastic cellularity

Formalin-fixed cytology cell block:  One H&E slide and 15-20 unstained cell block sections with a minimum of 20-percent neoplastic cellularity

Fine needle aspiration specimen:  Cells suspended in CytoLyt or PreservCyt solution, preserved at room temperature no longer than eight days

Turnaround Time: 10-14 calendar days from receipt of material in the Clinical Genomics Laboratory

Request Form: Orderable in CoPath and EPIC (Oncomine Comprehensive NGS, with Pathologist Interpretation)

DNA requirements: 10 ng